Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07491367
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cartilage Damage
  • Knee Osteoarthristis
  • Platelet Rich Plasma
  • Platelet Rich Plasma Injection

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Platelet Rich Plasma — BIOLOGICAL
    The Platelet Rich Plasma (PRP) participants will receive in this study will be made by Emcyte PurePRP Supraphysiologic Concentrating System or the APEX Biologix XCELL PRP System.
  • Emcyte PurePRP Supraphysiologic Concentrating System — DEVICE
    Platelet Rich Plasma (PRP) will be made by the Emcyte PurePRP Supraphysiologic Concentrating System.
  • APEX Biologix XCELL PRP System — DEVICE
    Platelet Rich Plasma (PRP) will be made by APEX Biologix XCELL PRP System.

Study Details

The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.

Key Dates

Start date
Jul 1, 2026
Status verified
Jun 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: APEX Biologix XCELL PRP System
    Participants in this group will receive Platelet Rich Plasma made by the APEX Biologix XCELL PRP System.
  • Active Comparator: Emcyte PurePRP Supraphysiologic Concentrating System
    Participants in this group will receive Platelet Rich Plasma made by Emcyte PurePRP Supraphysiologic Concentrating System.

Primary Outcome Measure

Cellular composition and quantity using Horiba Cell counter [ Time Frame: Day 1 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California San FranciscoSan FranciscoCalifornia94158
Jocelyn Carpio
[email protected]
415-502-4548
Anthony Luke, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California San Francisco· San Francisco, CA

Related Studies